Home・Aandelen Lijst・Fate Therapeutics Inc

Fate Therapeutics Inc

Gesloten

SectorGezondheidszorg

2.79 12.5

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

2.77

Max

2.86

Belangrijke statistieken
By Trading Economics
Inkomsten	1.2M -31M
Verkoop	-70K 1.3M
EPS	-0.26
Winstmarge	-2,402.848
Werknemers	161
EBITDA	14M -28M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+87.14% upside

Dividenden
By Acuity
Volgende Winsten	10 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	38M 291M
Vorige openingsprijs	-9.71
Vorige sluitingsprijs	2.79

Nieuwssentiment

By Acuity

50%

128 / 340 Rangschikking in Healthcare

Fate Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

7 aug 2026, 20:03 UTC

Fate Therapeutics shares are higher, reaching a session high amid rising U.S. Treasury yields and a weakening U.S. Dollar Index. No specific news identified.

6 aug 2026, 19:26 UTC

Correlated Moves

Fate Therapeutics Inc shares are lower today, reflecting broader market trends and a decline in the Russell 2000 Index amid ongoing inflation concerns.

5 aug 2026, 19:56 UTC

Fate Therapeutics shares are higher amid positive market sentiment and falling oil prices, despite some volatility during Wednesday's trading session.

4 aug 2026, 20:07 UTC

News

Correlated Moves

Fate Therapeutics is gaining as it announces employee inducement awards, including stock options at $2.45 per share. Shares rebounded after an earlier pullback.

3 aug 2026, 23:01 UTC

News

Fate Therapeutics Inc. shares are lower in after-market trading, despite stronger growth in the manufacturing sector and recent employee inducement awards.

29 jul 2026, 19:19 UTC

Fate Therapeutics is trading higher amid positive market momentum ahead of the Federal Reserve's monetary policy announcement, despite lingering inflation concerns.

28 jul 2026, 16:06 UTC

Fate Therapeutics shares are lower amid broader market weakness and investor caution ahead of key earnings reports and the Federal Reserve's interest rate decision.

27 jul 2026, 21:02 UTC

Fate Therapeutics shares are higher in after-market hours, despite no specific news. Broader market sentiment is improving with rising European equity indices.

24 jul 2026, 19:07 UTC

Correlated Moves

Fate Therapeutics shares are lower, pressured by a notable decline in first-quarter results and broader market sentiment. They remain below the 20-day moving average.

23 jul 2026, 21:11 UTC

Fate Therapeutics Inc. shares are higher in after-market hours, reflecting broader market gains. No specific company news has been identified to explain this increase.

22 jul 2026, 23:46 UTC

Fate Therapeutics Inc shares are higher in after-market trading, reflecting a modest gain since Wednesday's close, despite no specific news identified.

20 jul 2026, 18:26 UTC

Fate Therapeutics Inc. shares are effectively unchanged as trading remains flat. The stock has seen strong performance over the past month, nearing its recent highs.

Peer Vergelijking

Prijswijziging

Fate Therapeutics Inc Prognose

Koersdoel

By TipRanks

87.14% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 5.24 USD 87.14%

Hoogste 8 USD

Laagste 2.2 USD

Gebaseerd op 9 Wall Street-analisten die 12-maands prijsdoelen bieden voor Fate Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

9 ratings

Buy

Hold

Sell

Gebaseerd op 9 analisten die aandelenratings hebben gegeven aan Fate Therapeutics Inc - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

128 / 340 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.